TB is now the World’s Leading Infectious Killer
Tuberculosis is now the leading infectious disease threat in the world, killing more people than HIV/AIDS, as reported today by […]
News
TB Alliance Launches “Nix-TB” Clinical Trial to Test New XDR-TB Treatment
TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant
Host for new TB clinical trial data-sharing platform selected
TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB)
TB Alliance Announces Partnership with U.S. Fund for UNICEF to Increase Access to Impending New Child-Friendly TB Treatments
TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and
CPTR Marks Fifth Anniversary, Launches New Website
Critical Path to TB Drug Regimens (CPTR), an initiative that brings together the world’s leading pharmaceutical companies, product development sponsors,
Australia Grants Support for TB Alliance to Advance New TB Drugs
TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB),
News
The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard
Global Phase 3 “STAND” Trial Launched to Test New Tuberculosis Drug Regimen PaMZ to Shorten, Improve Treatment
* STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America
News
TB Alliance Advances Next-generation TB Drug Candidate into Clinical Testing
TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354.
News
Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824)
A promising new tuberculosis (TB) drug regimen, which could improve the treatment of drug sensitive TB and multi-drug resistant (MDR-)